Sumycin

Acinetobacter Infections, Rocky Mountain Spotted Fever, Psittacosis + 46 more

Treatment

64 FDA approvals

20 Active Studies for Sumycin

What is Sumycin

Tetracycline

The Generic name of this drug

Treatment Summary

Tetracycline is an antibiotic used to treat bacterial infections. It works by preventing bacteria from making proteins necessary for their growth. Tetracycline binds to the ribosomes, which are components of the bacterial cell, and causes them to leak, leading to the death of the bacteria.

Tetracycline Hydrochloride

is the brand name

image of different drug pills on a surface

Sumycin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tetracycline Hydrochloride

Tetracycline

1975

59

Approved as Treatment by the FDA

Tetracycline, also known as Tetracycline Hydrochloride, is approved by the FDA for 64 uses which include Lower respiratory tract infection bacterial and Campylobacter Infections .

Lower respiratory tract infection bacterial

Campylobacter Infections

Bacteria

Acinetobacter Infections

Chlamydia Infections

Bacterial Infections

Tularemia

Bacterial Infections

Clostridium Infections

Severe Acne

Escherichia infections

Trachoma

Anthrax disease

Inclusion conjunctivitis

Relapsing Fever

Brucellosis

Necrotizing ulcerative gingivostomatitis

Entamoeba histolytica Infection

Neisseria Gonorrhoeae Infection

Psittacosis

Klebsiella Infections

Brucellosis

Disease

Bacteria

Q Fever

Plague

Conjunctivitis, Inclusion

Relapsing Fever

Listeriosis

Gonorrhea

Yaws

Acne Vulgaris

Syphilis

Cholera (Disorder)

Fever

Urinary Tract Infections

Dysentery, Bacillary

Urinary Tract Infection (UTI)

Typhus

Infection, Bacteroides

Campylobacter Infection

Granuloma Inguinale

Trachoma

Clostridium difficile Infection

Listeria infection

Cat-Scratch Disease

Upper respiratory tract infection bacterial

Helicobacter Pylori Infection

Used to treat Helicobacter Pylori Infection in combination with Metronidazole

Acinetobacter Infections

Yaws

Plague

Chlamydial Infections

Tularemia

Ornithosis

Escherichia coli Infections

Anthrax

Chancroid

Skin Infections caused by Staphylococcus Aureus

Actinomycosis

Shigella Infection

Lymphogranuloma Venereum

Rickettsialpox

Rocky Mountain Spotted Fever

Skin and Subcutaneous Tissue Bacterial Infections

Effectiveness

How Sumycin Affects Patients

Tetracycline is a short-term antibiotic that works by blocking the ability of bacteria to make proteins. It does this by attaching to parts of the bacteria's cells, which prevents the bacteria from making the proteins it needs to survive. Tetracycline can also weaken the outer membrane of the bacteria, causing it to leak out important molecules it needs to survive.

How Sumycin works in the body

Tetracycline works by blocking the production of proteins in bacteria. It enters the bacterial cells and binds to their ribosomes, preventing tRNA molecules from translating the genetic code into proteins. This stops the bacteria from making proteins, which kills them.

When to interrupt dosage

The proposed measure of Sumycin is contingent upon the diagnosed affliction, including Bartonellosis, Skin Infections induced by Staphylococcus Aureus and Clostridium difficile Infection (CDI). The amount of dosage relies upon the method of administration detailed in the table beneath.

Condition

Dosage

Administration

Anthrax

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Syphilis

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Rocky Mountain Spotted Fever

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Trachoma

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Acute Glomerulonephritis

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Urinary tract infection

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Cat-Scratch Disease

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Brucellosis

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Bacteria

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Bacteria

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Actinomycosis

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Rosacea

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Helicobacter Pylori Infection

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Ornithosis

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Clostridium difficile Infection

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Entamoeba histolytica Infection

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Urinary Tract Infections

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Listeriosis

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Bacterial Infections

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Necrotizing ulcerative gingivostomatitis

, 250.0 mg, 500.0 mg, 30.0 mg/mL, 0.03 mg/mL, 0.03 mg/mg, 125.0 mg, 1.0 %, 12.7 mg, 1.5 mg/mg, 125.0 mg/mL, 0.01 mg/mg

Oral, Capsule - Oral, Capsule, , Ointment, Ointment - Topical, Topical, Kit - Oral, Kit, Ointment - Ophthalmic, Ophthalmic, Tablet, Tablet - Oral, Liquid - Oral, Liquid, Dental, Tablet, film coated, Tablet, film coated - Oral, Syrup, Syrup - Oral, Spray - Topical, Spray

Warnings

There are 20 known major drug interactions with Sumycin.

Common Sumycin Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Tetracycline.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Tetracycline.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Tetracycline.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Tetracycline.

Amdinocillin

Major

The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Tetracycline.

Sumycin Toxicity & Overdose Risk

The lethal dose of the drug in mice when taken orally is 808mg/kg.

image of a doctor in a lab doing drug, clinical research

Sumycin Novel Uses: Which Conditions Have a Clinical Trial Featuring Sumycin?

45 active trials are investigating the potential of Sumycin in the management of Klebsiella Infections, Rocky Mountain Spotted Fever and Granuloma Inguinale.

Condition

Clinical Trials

Trial Phases

Chancroid

0 Actively Recruiting

Escherichia coli Infections

5 Actively Recruiting

Not Applicable, Phase 2, Phase 1

Rickettsialpox

0 Actively Recruiting

Rosacea

2 Actively Recruiting

Early Phase 1, Phase 2

Clostridium difficile Infection

0 Actively Recruiting

Listeriosis

0 Actively Recruiting

Dysentery, Bacillary

0 Actively Recruiting

Campylobacter Infections

0 Actively Recruiting

Plague

0 Actively Recruiting

Trachoma

1 Actively Recruiting

Phase 4

Infection

6 Actively Recruiting

Not Applicable, Phase 1

Bacteria

0 Actively Recruiting

Psittacosis

0 Actively Recruiting

Klebsiella Infections

0 Actively Recruiting

Rocky Mountain Spotted Fever

0 Actively Recruiting

Relapsing Fever

0 Actively Recruiting

Prostatitis

0 Actively Recruiting

Tularemia

0 Actively Recruiting

Granuloma Inguinale

0 Actively Recruiting

Cat-Scratch Disease

0 Actively Recruiting

Sumycin Reviews: What are patients saying about Sumycin?

3

Patient Review

9/21/2012

Sumycin for Sepsis Caused by Bacteria

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sumycin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which drugs are tetracyclines?

"Adoxa, Adoxa CK, Adoxa Pak, Brodspec, Cleeravue-M, Declomycin, Doryx, and Dynacin are all medicines."

Answered by AI

How do you take sumycin?

"An adult dose of Sumycin is 1 gram (g), taken four times a day for 7 to 10 days. A child's dose of Sumycin is based on weight.

How to use Sumycin Tablet:

Tetracycline works best when taken on an empty stomach 1 hour before or 2 hours after meals. If stomach upset occurs, ask your doctor if you can take this medication with food.

Take each dose with a full glass of water (8 ounces or 240 milliliters) unless your doctor directs you otherwise.

An adult dose of Sumycin is 1 gram (g), taken four times a day for 7 to 10 days. A child's dose of Sumycin is based on weight."

Answered by AI

What is the most common side effect of tetracyclines?

"If you experience any of the following side effects, tell your doctor or pharmacist immediately as they may worsen over time. These include: nausea, vomiting, diarrhea, loss of appetite, mouth sores, black hairy tongue, sore throat, dizziness, headache, or rectal discomfort."

Answered by AI

What is sumycin used for?

"Tetracycline hydrochloride, sold under the brand name Sumycin among others, is an antibiotic used to treat a number of infections. This includes acne, chlamydia, gonorrhea, urinary tract infections, and others. It is taken by mouth."

Answered by AI

Clinical Trials for Sumycin

Image of University of North Carolina in Chapel Hill, United States.

BLTR vs B-RAP for Trichiasis

18+
All Sexes
Chapel Hill, NC

The primary objective of this randomized clinical trial is to determine whether repeat trichiasis surgery performed with Bevel-Rotate Advancement Procedure (B-RAP) improves surgical success compared to Bilamellar Tarsal Rotation (BLTR) among a group of 8-10 TT surgeons in Tanzania. The study aims to enroll 1,000 individuals with PTT. The primary outcome is repeat PTT within one year after surgery. Additionally, the study will assess eyelid contour abnormalities and how they change over a two-year period as well as patient reported outcomes. If this project is successful in improving surgical outcomes, it could change the approach to treating PTT globally. Individuals with trichiasis have a significantly reduced quality of life; correcting their trichiasis long-term has the potential to improve their quality of life and their family members' quality of life considerably.

Waitlist Available
Has No Placebo

University of North Carolina

Emily Gower, PhD

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Medstar National Rehabilitation Hospital in Washington D.C., United States.

Lactobacillus Crispatus for Urinary Tract Infection

18+
All Sexes
Washington D.C., United States

The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question\[s\] it aims to answer are: 1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC). 2. To determine if intravesical instillation of L. crispatus is safe and well tolerated in adults with NLUTD due to SCI who use intermittent catheterization (IC). If there is a comparison group: Researchers will compare L. Crispatus to standard care saline to see if there is a difference in urinary symptoms and urinary microbiome. Participants will be asked to complete daily symptom surveys, complete 2 bladder instillations, and collect, freeze, and return 14 urine samples.

Phase < 1
Recruiting

Medstar National Rehabilitation Hospital

Suzanne Groah, MD

Have you considered Sumycin clinical trials?

We made a collection of clinical trials featuring Sumycin, we think they might fit your search criteria.
Go to Trials
Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD

Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA

At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.

Waitlist Available
Has No Placebo

UPMC Magee-Womens Hospital

Anna Binstock, MD

Have you considered Sumycin clinical trials?

We made a collection of clinical trials featuring Sumycin, we think they might fit your search criteria.
Go to Trials
Image of Queens Medical Center, 1004 Clinic POB1 in Honolulu, United States.

Self-swab Testing for STDs

Any Age
Female
Honolulu, HI

The goal of this interventional study is to provide more access to STI testing for patients who seek abortion care through telemedicine, particularly for those whose access to STI testing is otherwise limited. The main questions it aims to answer are: What is the acceptability, feasibility, and utilization of self-collected STI screening at the time of telemedicine medication abortion provision? How does the uptake of such a service among patients receiving telemedicine abortion care compare to the population of patients who seek in-person medication abortion care? What are the positivity rates for STIs in among patients receiving telemedicine medication abortion care compared to the positivity rates for a contemporaneous, in-clinic population? What is the average time to between testing and treatment for patients who test positive for an STI using the self-collection service? Researchers will compare the intervention group to a contemporaneous, in-clinic population on uptake of STI screening, as well as on positivity rates for the STIs tested. Participants will be asked to perform self-swab collection for STI testing for gonorrhea, chlamydia, and trichomonas. They will be instructed to send their specimens to a lab using prepaid postage. Upon completion of sample collection and shipping, they will be asked to complete a survey assessing basic demographic information, as well as acceptability and feasibility of the intervention. Patients who test positive for an STI will be promptly provided/referred to treatment.

Recruiting
Has No Placebo

Queens Medical Center, 1004 Clinic POB1

Have you considered Sumycin clinical trials?

We made a collection of clinical trials featuring Sumycin, we think they might fit your search criteria.
Go to Trials